Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Deffered Revenue (2020 - 2021)

Oncology Institute (TOI) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $6.3 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Non-Current Deffered Revenue changed 0.0% year-over-year to $6.3 million, compared with a TTM value of $6.3 million through Sep 2021, changed 0.0%, and an annual FY2020 reading of $6.3 million, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $6.3 million for Q3 2021 at Oncology Institute, roughly flat from $6.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $6.3 million in Q1 2020 and bottomed at $6.3 million in Q1 2020.